Actively Recruiting
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Led by St. Jude Children's Research Hospital · Updated on 2026-05-08
90
Participants Needed
10
Research Sites
290 weeks
Total Duration
On this page
Sponsors
S
St. Jude Children's Research Hospital
Lead Sponsor
P
Pfizer
Collaborating Sponsor
AI-Summary
What this Trial Is About
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm. In Arm A, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and talazoparib. Onivyde works by damaging the DNA of the cancer cell and talazoparib works by blocking the repair of the DNA once the cancer cell is damaged. By damaging the tumor DNA and blocking the repair, the cancer cells may die. In Arm B, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and temozolomide. Both of these medications work by damaging the DNA of the cancer call which may cause the tumor(s) to die. Once the highest doses are reached in Arm A and Arm B, then "expansion Arms" will open. An expansion arm treats more children and AYAs with recurrent or refractory solid tumors at the highest doses achieved in the phase I study. The goal of the expansion arms is to see if the tumors go away in children and AYAs with recurrent or refractory solid tumors. There will be 3 "expansion Arms". In Arm A1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and talazoparib. In Arm A2, children and AYAs with recurrent or refractory solid tumors, whose tumors have a problem with repairing DNA (identified by their doctor), will receive Onivyde and talazoparib. In Arm B1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and temozolomide. Once the highest doses of medications used in Arm A and Arm B are determined, then a phase II study will open for children or young adults with Ewing sarcoma that has recurred or is refractory following treatment received after the initial diagnosis. The trial will test the same 2 combinations of therapy in Arm A and Arm B. In the phase II, a participant with Ewing sarcoma will be randomly assigned to receive the treatment given on either Arm A or Arm B.
CONDITIONS
Official Title
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be over 12 months and under 30 years old at enrollment.
- Phase I: Patients with refractory or recurrent non-CNS solid tumors with histologic verification are eligible.
- Patients eligible for expansion cohort A2 must have defects in DNA repair genes confirmed by prior testing.
- Phase II: Patients with refractory or recurrent Ewing sarcoma after first-line therapy.
- Histologic diagnosis of Ewing sarcoma with specific genetic markers is required.
- Patients must have measurable or evaluable disease.
- Performance score above 50% (Karnofsky for >16 years, Lansky for <16 years).
- Prior irinotecan- or temozolomide-based therapy allowed in phase I; prior PARP inhibitors other than talazoparib allowed.
- Phase II patients must have adequate organ and bone marrow function as defined by lab values.
- Patients must have recovered from acute effects of prior treatments.
- Post-menarchal females must have a negative pregnancy test and agree to ongoing testing.
- Participants of reproductive potential must agree to use effective contraception during the study.
You will not qualify if you...
- Pregnant or breastfeeding individuals are not eligible.
- Participants unwilling to use two forms of birth control during and after treatment.
- Patients who donate sperm or eggs during and shortly after the study treatment period are excluded.
- Females not of childbearing potential include those surgically sterile.
- Patients with ongoing severe toxicities or conditions preventing treatment continuation are excluded.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Lucille Packard Children's Hospital Stanford
Palo Alto, California, United States, 94304
Actively Recruiting
2
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
Actively Recruiting
3
Children's National Medical Center
Washington D.C., District of Columbia, United States, 20010
Actively Recruiting
4
Children's Healthcare of Atlanta/Emory University School of Medicine
Atlanta, Georgia, United States, 30322
Not Yet Recruiting
5
Children's Hospital and Clinics of Minn
Minneapolis, Minnesota, United States, 55404
Actively Recruiting
6
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105
Actively Recruiting
7
Texas Children's Hospital/ Baylor College of Medicine
Houston, Texas, United States, 77030
Active, Not Recruiting
8
The Hospital for Sick Children
Toronto, Ontario, Canada
Actively Recruiting
9
CHU Sainte-Justine
Montreal, Canada
Actively Recruiting
10
BC Children's Hospital Research Institute
Vancouver, Canada
Not Yet Recruiting
Research Team
S
Sara Federico, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here